PDE5A and pulmonary arterial hypertension: Originally used for erectile dysfunction and pulmonary hypertension, PDE-5 inhibitors increase cyclic guanosine monophosphate (cGMP) levels and intracellular nitric oxide (NO), leading to vasodilation [16].